Amylyx’s Relvyvrio data was, as promised, disappointing

STAT April 17, 2024
Meghana Keshavan

So the GLP-1s strike again: Eli Lilly’s Zepbound seems to work in obstructive sleep apnea as well. Beyond that, we see up close how Amylyx’s ALS drug — which it is pulling from the market — really didn’t differ much from placebo, and see more market and investment potential for psychedelics.

The need-to-know this morning

• Sage Therapeutics said an experimental drug failed to improve cognition versus a placebo in a mid-stage study of Parkinson’s disease. The company is conducting additional studies of the drug, called SAGE-718, in Huntington’s disease and Alzheimer’s disease, with results expected later this year.
• Brainstorm Cell Therapeutics, a developer of a cell therapy for ALS, said its co-CEO, Stacy Lindborg, is leaving the company.
• Future...

Today's Sponsors

Today's Sponsor